<DOC>
	<DOCNO>NCT00798135</DOCNO>
	<brief_summary>Cancer cell need able make new blood vessel order keep grow . This call angiogenesis . In laboratory setting , drug itraconazole show help stop growth new blood vessel ( anti-angiogenesis ) . It hop itraconazole prevent new blood vessel form human . The purpose study look body process breaks itraconazole ( call pharmacokinetics ) . This study also measure marker blood see itraconazole stop new blood vessel form . The safety itraconazole also test see effect ( good bad ) breast cancer .</brief_summary>
	<brief_title>A Pilot Trial Itraconazole Pharmacokinetics Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Patients must pathologically confirm diagnosis invasive carcinoma breast . Patients must carry diagnosis metastatic breast cancer . Patients must able swallow oral medication . Patients HER 2+ tumor must receive trastuzumab past may lapatinib . Patients must ECOG performance status 01 . Patients must inform investigational nature study must sign give write informed consent . Patients must recover grade &lt; 1 acute toxicity previous therapy breast cancer exception alopecia . Adequate hematologic hepatic function : 1 ) Absolute neutrophil count &gt; = 1,500 mm3 2 ) Platelet count &gt; = 100,000 mm3 3 ) Bilirubin &lt; = 1.5mg/dL x ULN 4 ) AST and/or ALT &lt; = 2 x ULN ( &lt; 5 x ULN presence know liver metastasis ) . Prior study enrollment , woman childbearing potential ( WOCBP ) must advise importance avoid pregnancy trial participation must practice effective method birth control . In addition , men enrol study understand risk sexual partner childbearing potential also practice effective method birth control . All WOCBP MUST negative serum urine pregnancy test within 4 week prior start study drug administration . Use follow concomitant medication within 14 day start protocol therapy prohibit : Cisapride , dofetilide , ergot derivative , levomethadyl , lovastatin , midazolam , pimozide , quinidine , simvastatin , triazolam . Patients take alprazolam ( Xanax ) exclude trial . Patients must active infection require use intravenous antibiotic . The use oral antibiotic allow . Hypersensitivity itraconazole , component formulation , azoles . Patients uncontrolled CNS metastasis exclude . If patient CNS metastasis must complete brain radiation least 2 week prior registration must steroids CNS metastasis . Known preexist congestive heart failure leave ventricular dysfunction . Patients risk factor ( ex . uncontrolled hypertension BP &gt; 160/90 ) cardiac dysfunction preexist diagnosis congestive heart failure leave ventricular dysfunction screen EKG prior enrollment . Subsequently , patient abnormal EKG , judge treat physician , exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>